Annovis Bio, Inc.

Redefining the Global Future of Aging and Neurodegeneration

NYSE: ANVS

Our company is developing a first-in-class therapy aimed at stopping or even reversing neurodegeneration in Alzheimer's (AD) and Parkinson's (PD) diseases. Decades of research have shown that neurodegenerative diseases follow a similar biological cascade: neurons become stressed, dysfunctional, and eventually die. Dysfunctional nerve cells cause defective behavior, and dead nerve cells cause loss of function. Buntanetap reverses this toxic cascade resulting in improved cognition and function in AD and PD. In comparison, existing treatments show very modest benefits, and no approved therapy targets the whole toxic cascade that leads to nerve cell death. To date, only our drug - buntanetap - can protect nerve cells from dying.

Healthcare Paradox

- Better healthcare infrastructure results in longer life expectancy, which leads to surging cases of AD and PD.
- By 2050, 71% of future AD and PD cases will be in low- and middle-income countries, where 2 billion people lack access to essential medicines.

> *"Medical progress has given us longer lives—now we need treatments that make those years worth living."*

Market and Economic Burden

Neurodegenerative diseases represent one of the largest and fastest growing unmet medical needs worldwide:

- Parkinson's disease affects **>10 million people globally with the market estimated at $9-10 billion.**
- Alzheimer's disease affects **>55 million people with the current generic market of $7-8 billion.**
- However, once there are drugs that stop the disease, the nascent market for disease-modifying treatments is estimated to be over **$100 billion.**





Buntanetap Eliminates Every Barrier That Prevents Global Access

Buntanetap represents a paradigm shift – not just in how we treat neurodegeneration, but in who can access that treatment. As a simple pill, buntanetap addresses the biological complexity of neurodegenerative diseases, delivering efficacy and equity. The drug can be prescribed by primary care doctors and taken daily at home.

What Makes Buntanetap a Game Changer?

Its mechanism addresses multiple neurodegenerative diseases through a single biological pathway.

The program is de-risked by unusually high alignment of animal and human efficacy as well as mechanistic data.

Buntanetap has been tested in over 1,200 patients and showed statistically significant efficacy in cognition and function in a total four AD and PD studies.

Last Clinical Trials Before Market Approval

Currently we are conducting a double-blind, placebo-controlled pivotal 18-month Phase 3 study in 700-760 AD patients. We are also conducting an open-label PD study with 500-600 patients.



- Annovis has shown in the Phase 2/3 trial that its drug buntanetap works in early AD.
- The FDA has given clear guidance: replicating these results in a larger population will allow to file for New Drug Application (NDA).
- The pivotal Phase 3 trial is approaching full enrollment with pivotal data expected in early 2027.

If Annovis' study succeeds, the drug may be on the market in 2027/2028. Further, the implications for buntanetap extend beyond Alzheimer's disease, representing a massive opportunity to change the treatment landscape for cognitive decline.

Comparison with Approved Drugs



- Current standard-of-care medications (i.e. Aricept) provide only temporary symptomatic relief, with benefits typically diminishing after six months.
- Recently approved disease-modifying treatments (Leqembi, Kisunla) slow cognitive decline by approximately 30% but do not improve cognition.
- Buntanetap has demonstrated symptomatic improvements beyond the standard-of-care and holds the potential for disease modification, which is being evaluated in the ongoing pivotal Phase 3 study.

Efficacy of Buntanetap

Buntanetap significantly improves cognition across four studies in AD and PD.



Target patient group



Buntanetap shows a unified and reproducible treatment pattern: profound cognitive benefit in patients with mild dementia (MMSE >20) and biomarker-confirmed presence of amyloid and tau.

Contact

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

+1 (484) 875-3192
info@annovisbio.com

@annovisbio
Annovis Bio, Inc.